Parvovirus VP2
Sterile Filtered White lyophilized (freeze-dried) powder.
Greater than 90.0% as determined by SDS-PAGE.
Description
Recombinant canine Parvovirus VP2 produced in SF9 is a glycosylated, polypeptide chain containing 584 a.a and having a calculated molecular mass of 64,657 Dalton. Parvovirus VP2 is purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Canine parvovirus (CPV) is a highly contagious viral disease that affects dogs, causing severe gastrointestinal and cardiac issues. The virus is particularly dangerous for puppies, leading to high mortality rates. The VP2 protein of CPV is a major structural protein and a key antigen used in vaccine development. Recombinant VP2 protein has been explored as a potential subunit vaccine to provide immunity against CPV.
CPV belongs to the Parvoviridae family and is a non-enveloped, single-stranded DNA virus. It was first identified in 1978 and rapidly spread worldwide, becoming a significant threat to the dog breeding industry . The virus primarily affects the intestinal tract and the heart, leading to symptoms such as vomiting, diarrhea, and myocarditis.
The VP2 protein is the most abundant structural protein of CPV, making up about 90% of the viral capsid . It plays a crucial role in determining the virus’s tissue tropism and host range. The VP2 protein is also the primary target for neutralizing antibodies, making it an ideal candidate for vaccine development .
Recombinant VP2 protein is produced using various expression systems, such as baculovirus, to create a subunit vaccine. This approach aims to overcome the limitations of traditional inactivated and live-attenuated vaccines, which can be expensive and labor-intensive to produce . The recombinant VP2 protein can self-assemble into virus-like particles (VLPs), which mimic the native virus and elicit a strong immune response .
Studies have shown that the recombinant VP2 protein can induce high levels of hemagglutination inhibition antibodies in animal models, such as mice . This indicates its potential as an effective subunit vaccine against CPV. The use of recombinant VP2 protein in vaccines offers several advantages, including safety, stability, and the ability to produce large quantities at a lower cost .
